 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE, a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the first subject has been dosed in a Phase 1a study of BX002, a phage therapy candidate for the treatment of inflammatory bowel disease IBD. The first-in-human study is designed to evaluate the safety, pharmacokinetics, and ability of orally-administered BX002 to deliver viable phage to 